P
Paul M. Hassoun
Researcher at Johns Hopkins University
Publications - 308
Citations - 16671
Paul M. Hassoun is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pulmonary hypertension & Medicine. The author has an hindex of 61, co-authored 267 publications receiving 14372 citations. Previous affiliations of Paul M. Hassoun include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Innate Immunity against Bacterial Infection following Hyperoxia Exposure Is Impaired in NRF2-Deficient Mice
Narsa M. Reddy,Vegiraju Suryanarayana,Dhananjaya V. Kalvakolanu,Masayuki Yamamoto,Thomas W. Kensler,Paul M. Hassoun,Steven R. Kleeberger,Sekhar P. Reddy +7 more
TL;DR: It is shown that Nrf2-deficient but not wild-type mice exposed to sublethal hyperoxia succumbed to death during recovery after Pseudomonas aeruginosa infection, leading to death of the host.
Journal ArticleDOI
Resistin-Like Molecule-β in Scleroderma-Associated Pulmonary Hypertension
Daniel J. Angelini,Qingning Su,Kazuyo Yamaji-Kegan,Chunling Fan,Xingwu Teng,Paul M. Hassoun,Stephen C. Yang,Hunter C. Champion,Rubin M. Tuder,Roger A. Johns +9 more
TL;DR: Results suggest that RELM-beta may be involved in the development of scleroderma-associated pulmonary hypertension.
Journal ArticleDOI
Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension.
François Potus,Michael W. Pauciulo,Elina K. Cook,Na Zhu,Alexander Hsieh,Carrie L. Welch,Yufeng Shen,Lian Tian,Patricia D.A. Lima,Jeffrey Mewburn,Christine L. D’Arsigny,Katie A. Lutz,Anna W. Coleman,Rachel L. Damico,Brooke Snetsinger,Ashley Martin,Paul M. Hassoun,William C. Nichols,Wendy K. Chung,Michael J. Rauh,Stephen L. Archer +20 more
TL;DR: PAH is the first human disease related to potential TET2 germline mutations and has potential as a PAH biomarker, as investigated in hematopoietic Tet2-knockout mice.
Journal ArticleDOI
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension
Jiwang Chen,Justin R. Sysol,Sunit Singla,Shuangping Zhao,Aya Yamamura,Aya Yamamura,Daniela Valdez-Jasso,Taimur Abbasi,Taimur Abbasi,Krystyna M. Shioura,Sakshi Sahni,Vamsi Reddy,Arvind Sridhar,Hui Gao,Hui Gao,Jaime Torres,Sara M. Camp,Haiyang Tang,Shui Quing Ye,Suzy A. A. Comhair,Raed A. Dweik,Paul M. Hassoun,Jason X.-J. Yuan,Joe G.N. Garcia,Roberto F. Machado +24 more
TL;DR: Evidence is provided that NAMPT plays a role in pulmonary vascular remodeling and that its inhibition could be a potential therapeutic target for pulmonary arterial hypertension.
Journal ArticleDOI
Noninvasive Imaging in the Assessment of the Cardiopulmonary Vascular Unit
TL;DR: Although echocardiography is the mainstay in the assessment of hemodynamic and ventricular function in PH, MRI has emerged as the gold standard for quantifying volumes, function, and flow in the right side of the heart.